← Back to Search

Exparel vs Marcaine for Pain Management After Knee Replacement

N/A
Waitlist Available
Research Sponsored by Rothman Institute Orthopaedics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All patients at least 18 years old who have primary unilateral TKA for osteoarthritis performed at Thomas Jefferson University Hospital.
Be older than 18 years old
Must not have
Body weight<50 Kg, BMI>40 Kg/m2
Renal disease (contraindication for NSAIDs)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

This trial is testing whether Exparel is better than Marcaine at controlling pain and reducing side effects related to narcotics while also considering patient satisfaction and outcomes measures. The investigators will also analyze whether the higher price of Exparel is worth it based on factors like decreased need for postoperative pain medication and physical therapy.

Who is the study for?
This trial is for adults over 18 who need a knee replacement due to osteoarthritis at Thomas Jefferson University Hospital. It's not for those with severe anesthesia risks, kidney or liver disease, certain drug allergies, low blood pressure history, extreme body weight issues, recent substance abuse, or chronic opioid use.
What is being tested?
The study compares Exparel and Marcaine as pain management drugs after knee surgery. It looks at how well they control pain, affect narcotic use and side effects, patient satisfaction and recovery outcomes including hospital stay length and physical therapy needs.
What are the potential side effects?
Possible side effects of Exparel and Marcaine include reactions at the injection site like swelling or pain; systemic reactions such as nausea or vomiting; nerve damage symptoms like numbness; allergic responses; and potential impact on heart rate.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 and had a knee replacement at Thomas Jefferson University Hospital due to arthritis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I weigh less than 50 kg or my BMI is over 40.
Select...
I cannot take certain pain relievers due to kidney disease.
Select...
I cannot take acetaminophen due to liver disease.
Select...
I cannot have injections into my spinal fluid.
Select...
I am currently taking MAO inhibitors or tricyclic antidepressants.
Select...
I have been using opioid medications regularly for the last month.
Select...
I have a history of low blood pressure.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: MarcaineActive Control1 Intervention
Group II: ExparelActive Control1 Intervention

Find a Location

Who is running the clinical trial?

Rothman Institute OrthopaedicsLead Sponsor
126 Previous Clinical Trials
22,584 Total Patients Enrolled

Media Library

Marcaine Clinical Trial Eligibility Overview. Trial Name: NCT02060591 — N/A
Total Knee Replacement Research Study Groups: Marcaine, Exparel
Total Knee Replacement Clinical Trial 2023: Marcaine Highlights & Side Effects. Trial Name: NCT02060591 — N/A
Marcaine 2023 Treatment Timeline for Medical Study. Trial Name: NCT02060591 — N/A
~30 spots leftby Nov 2025